NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Amgen Inc (NASDAQ: AMGN)

 
AMGN Technical Analysis
5
As on 26th Nov 2021 AMGN Share Price closed @ 201.09 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 237.77 & Strong Sell for SHORT-TERM with Stoploss of 230.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AMGN Share Price

Open 204.74 Change Price %
High 206.00 1 Day -2.88 -1.41
Low 200.52 1 Week -4.30 -2.09
Close 201.09 1 Month -5.69 -2.75
Volume 3197934 1 Year -44.32 -18.06
52 Week High 259.14 | 52 Week Low 201.09
 
NASDAQ USA Most Active Stocks
AAL 17.75 -8.79%
AAPL 156.81 -3.17%
ISPC 17.51 71.67%
SNDL 0.65 -4.41%
AHPI 8.32 54.65%
LCID 51.72 -1.62%
BIMI 0.90 28.57%
UAL 42.26 -9.57%
AMD 154.81 -1.89%
MRNA 329.63 20.57%
 
NASDAQ USA Top Gainers Stocks
ZWZZT 46.00 142.11%
NRXPW 3.10 78.16%
ISPC 17.51 71.67%
AHPI 8.32 54.65%
NRXP 6.75 50.00%
ATMH 0.16 45.45%
VOSOU 15.61 42.04%
ADGI 25.12 34.12%
PHIOW 0.04 33.33%
BOWXW 2.97 29.13%
 
NASDAQ USA Top Losers Stocks
IFMK 0.02 -93.10%
PTRAW 0.23 -89.59%
TPGY-WT 1.72 -83.65%
SGOC 5.37 -54.49%
STMP 0.02 -33.33%
STMP 0.02 -33.33%
CTXRW 0.40 -28.57%
SGAMU 10.45 -27.93%
LGVN 30.67 -27.49%
NOVVR 0.40 -25.93%
 
 
AMGN
Daily Charts
AMGN
Intraday Charts
Whats New @
Bazaartrend
AMGN
Free Analysis
 
AMGN Important Levels Intraday
RESISTANCE211.65
RESISTANCE208.26
RESISTANCE206.17
RESISTANCE204.08
SUPPORT198.10
SUPPORT196.01
SUPPORT193.92
SUPPORT190.53
 
AMGN Target for Month November
4th UP TARGET252.96
3rd UP TARGET236.33
2nd UP TARGET226.04
1st UP TARGET215.76
1st DOWN TARGET186.42
2nd DOWN TARGET176.14
3rd DOWN TARGET165.85
4th DOWN TARGET149.22
 
AMGN Weekly Target
4th UP TARGET248.07
3rd UP TARGET233.00
2nd UP TARGET223.69
1st UP TARGET214.38
1st DOWN TARGET187.80
2nd DOWN TARGET178.49
3rd DOWN TARGET169.18
4th DOWN TARGET154.11
 
AMGN Target for Year 2021
4th UP TARGET347.97
3rd UP TARGET300.86
2nd UP TARGET271.75
1st UP TARGET242.63
1st DOWN TARGET159.55
2nd DOWN TARGET130.43
3rd DOWN TARGET101.32
4th DOWN TARGET54.21
 
 
AMGN Other Details
Segment EQ
Market Capital 117641904128.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
AMGN Address
AMGN
 
AMGN Latest News
 
Your Comments and Response on Amgen Inc
 
AMGN Business Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
 
© 2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service